Development of humanized rabbit monoclonal antibodies against vascular endothelial growth factor receptor 2 with potential antitumor effects

Biochemical and Biophysical Research Communications

Volumn 436, Issue 3, 2013, Pages 543-550

  Yu, Yanlan ^a   Lee, Pierre ^b   Ke, Yaohuang ^b   Zhang, Yongke ^b   Chen, Jungang ^c   Dai, Jihong ^c   Li, Mingzhen ^c   Zhu, Weimin ^b   Yu, Guo Liang ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b Epitomics Inc   (United States)

^c Yikang Biotechnology Company   (China)

Author keywords

Angiogenesis; Anti angiogenic therapy; Rabbit monoclonal antibody; Vascular endothelial growth factor receptor 2

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; RABBIT MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CAPILLARY DENSITY; CONTROLLED STUDY; CROSS REACTION; DRUG BINDING; FEMALE; HUMAN; HUMAN CELL; HYBRIDOMA; IN VITRO STUDY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROTEIN INTERACTION;

ANGIOGENESIS; ANTI-ANGIOGENIC THERAPY; RABBIT MONOCLONAL ANTIBODY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; CROSS REACTIONS; FEMALE; HEK293 CELLS; HUMANS; HYBRIDOMAS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ORYCTOLAGUS CUNICULUS;

EID: 84879881075     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.007     Document Type: Article

References (20)

1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25:581-611.
2. Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000, 60:203-212.
3. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13:9-22.
4. Plate K.H., Breier G., Weich H.A., Mennel H.D., Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int. J. Cancer 1994, 59:520-529.
5. Yang S., Toy K., Ingle G., Zlot C., Williams P.M., Fuh G., Li B., de Vos A., Gerritsen M.E. Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1797-1803.
6. Dias S., Hattori K., Heissig B., Zhu Z., Wu Y., Witte L., Hicklin D.J., Tateno M., Bohlen P., Moore M.A., Rafii S. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc. Natl. Acad. Sci. USA 2001, 98:10857-10862.
7. Sher S.A., Adham J., Petrik B.L. Coomber, Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int. J. Cancer 2009, 124:553-561.
8. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
9. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355:2542-2550.
10. Spratlin J. Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr. Oncol. Rep. 2011, 13:97-102.
11. Klohs W.D., Hamby J.M. Antiangiogenic agents. Curr. Opin. Biotechnol. 1999, 10:544-549.
12. Rader C. Antibody libraries in drug and target discovery. Drug Discov. Today 2001, 6:36-43.
13. Yu Y., Lee P., Ke Y., Zhang Y., Yu Q., Lee J., Li M., Song J., Chen J., Dai J., Do Couto F.J., An Z., Zhu W., Yu G.L. A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS ONE 2010, 5:e9072.
14. Spieker-Polet H., Sethupathi P., Yam P.C., Knight K.L. Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Proc. Natl. Acad. Sci. USA 1995, 92:9348-9352.
15. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., Meli S., Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 1992, 84:1875-1887.
16. Jakobovits A., Amado R.G., Yang X., Roskos L., Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat. Biotechnol. 2007, 25:1134-1143.
17. Lee C.M., Iorno N., Sierro F., Christ D. Selection of human antibody fragments by phage display. Nat. Protoc. 2007, 2:3001-3008.
18. Molek P., Strukelj B., Bratkovic T. Peptide phage display as a tool for drug discovery: targeting membrane receptors. Molecules 2011, 16:857-887.
19. Liang W.C., Wu X., Peale F.V., Lee C.V., Meng Y.G., Gutierrez J., Fu L., Malik A.K., Gerber H.P., Ferrara N., Fuh G. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 2006, 281:951-961.
20. Popkov M., Mage R.G., Alexander C.B., Thundivalappil S., Barbas C.F., Rader C. Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J. Mol. Biol. 2003, 325:325-335.